INTRODUCTION {#S1}
============

Blood-based biomarkers, such as CA 125 (ovarian cancer), CEA (colorectal cancer), and PSA (prostate cancer), have established clinical utility as tools for early diagnosis and inexpensive, non-invasive methods of monitoring tumor recurrence or efficacy of therapy. While none of these biomarkers are 100% specific or sensitive, they are tremendously helpful in individual patients and have contributed to the more optimal care of patients with these cancer types. This is reflected in the fact that the mortalities from these 3 cancer types have been significantly decreasing ([@R1]). Endometrial cancer is the most common gynecological malignancy ([@R2]). The vast majority of endometrial cancers are endometrioid carcinomas diagnosed at an early stage ([@R3]). In contrast to colorectal cancer, prostate cancer, and ovarian cancer, the annual incidence and annual deaths from endometrial cancer are increasing ([@R1],[@R2]). The reasons for this increase in endometrial cancer-associated deaths are multi-factorial. One likely contributing factor is the lack of blood-based biomarkers in routine clinical use for these patients.

Analysis of circulating cell-free DNA via the "liquid biopsy" is emerging as a useful method to characterize tumor mutations. Plasma cell-free DNA is released into the peripheral blood by tumor cells and cells in the tumor microenvironment that undergo apoptosis or necrosis. While a number of recent publications have documented the utility and feasibility of analysis of mutations in cell-free DNA in pancreatic cancer ([@R4],[@R5]), colorectal cancer ([@R6]), and lung cancer ([@R7]), this approach has not yet been examined in endometrial cancer. Cicchillitti et al. ([@R8]) demonstrated that it is feasible to measure cell-free DNA from the plasma of endometrial cancer patients, but they did not attempt to identify plasma-based mutations. From previous studies of endometrial cancer patients treated at our institution, we have identified that alterations in *PTEN*, *PIK3CA*, *KRAS*, and *CTTNB1* are four of the most common molecular events in endometrioid-type endometrial carcinoma ([@R9], [@R10], [@R11]). These 4 genes have good sequencing coverage in a 50 gene hotspot next-generation sequencing panel employed in our clinical laboratory ([@R12]). Thus, we hypothesized that a small sequencing panel that covered these 4 genes could detect endometrioid-type endometrial carcinoma-associated mutations in the plasma of endometrial cancer patients.

METHODS AND MATERIALS {#S2}
=====================

Study cohort and patient data collection {#S3}
----------------------------------------

Forty-eight matched tumor-plasma-buffy coat samples from women diagnosed with endometrioid-type endometrial adenocarcinoma from 2011--2016 at the University of Texas MD Anderson Cancer Center were included in this proof-of-principle study. Patients included in the study were chosen based on the availability of sufficient plasma, white blood cell buffy coat, and sufficient formalin-fixed, paraffin-embedded endometrial carcinoma for amplicon-based next-generation sequencing. Endometrial cancer tissue and peripheral blood were both obtained at the time of hysterectomy. Peripheral blood was drawn into EDTA tubes, and the plasma and buffy coat fractions were separated within 12 hours of collection and stored at −80ºC. None of the 48 patients had chemotherapy or radiation therapy prior to hysterectomy. Representative H&E stained slides from each hysterectomy were reviewed by a gynecological pathologist (RRB) to confirm endometrioid histology and grade and determine estimated tumor cellularity. The demographic and clinical information were obtained by review of the pathology reports and the electronic medical record for each patient. Stages I and II (tumor confined to the uterus) were designated as early stage disease, while stages III and IV (tumor detected outside the uterus) were designated as late stage or advanced disease. The study was approved by the University of Texas MD Anderson Cancer Center's institutional review board (Protocol LAB01--718).

DNA extraction {#S4}
--------------

For each of the 48 cases, DNA was isolated from plasma, formalin-fixed, paraffin-embedded tumor, and buffy coat white blood cells. Circulating cell-free DNA was extracted from 3 ml of frozen plasma using the QIAamp Circulating Nucleic Acid Kit (QIAGEN, Valencia, CA). Using a mapped H&E stained slide as a guide, unstained slides of formalin-fixed, paraffin-embedded endometrial carcinoma were macro-dissected and then DNA extracted from the scraped tissue using the Arcturus PicoPure DNA Extraction Kit (Applied Biosystems, Thermo Fisher Scientific). Starting tumor percentage (per cent tumor cells in the mapped H&E stained slide) ranged from 50--90%. DNA from white blood cells was extracted from 300µl of thawed buffy coat using the Maxwell 16 LEV Blood DNA kit (Promega, Madison, WI). Quantification of DNA from all samples was performed on a Qubit Flourometer (Thermo Fisher Scientific) using the QUBIT DNA High-sensitivity (tumor DNA and cell-free DNA) and Broad Range (white blood cell DNA) assay kits (Life Technologies, Illkrich, France).

Next-generation sequencing {#S5}
--------------------------

A custom-designed Accel-Amplicon NGS panel 2.6 kb in size (Swift Biosciences, Ann Arbor, MI) covering hotspots in *PTEN* (exons 1,3,5,6,7,8)*, CTNNB1* (exon 3), *KRAS* (exons 2,3,4), and *PIK3CA* (exons 5,7,8,10,14,19,21) for Illumina platforms was used to profile tumor DNA, cell-free DNA, and white blood cell DNA. The average amplicon size for the 30 covered amplicons was 142 bp (range 119--187 bp). For these 4 genes, amplicon regions covered was similar to that for a 46 gene hotspot next-generation sequencing platform that we have previously described ([@R12]). Sequencing libraries were prepared and quantified as previously described ([@R13]). Quantified libraries were pooled, and the 20 pmol/l library was loaded on MiSeq Micro flow cell for paired-end sequencing using the MiSeq 300 Cycles version 2 kit (Illumina). Data analysis was performed using a custom bioinformatics pipeline ([@R13]). In cases with gene mutations detected at lower allelic fraction (less than 1%) in plasma cell-free DNA, libraries were re-sequenced in a standard flow cell at a higher depth to confirm the results obtained in the first analysis. For variant calling in the cell-free DNA, the filtering parameters were set as a minimum 250× sequencing depth and 25× variant coverage if the gene mutation allelic frequency was below 0.5%. Mutations called had to be present in the matching tumor DNA at ≥5% allelic frequency. All mutation calls were verified by visual inspection of the sequencing results using IGV.

Assessment of DNA mismatch repair {#S6}
---------------------------------

Mismatch repair protein and microsatellite instability testing were performed according to methodology previously described ([@R14]). Immunohistochemistry of mismatch repair proteins was performed using standard techniques for MLH1 (G168--15 1:25; BD Biosciences Pharmingen), MSH2 (FE11, 1:100; Calbiochem), MSH6 (44, 1:300; BD Biosciences Pharmingen), and PMS2 (Alb-4, 1:125; BD Biosciences Pharmingen). Immunohistochemistry was scored as mismatch repair protein intact or deficient using light microscopic examination. Complete absence of mismatch repair protein expression was required in order for a case to be designated as mismatch repair deficient. Stromal cells served as an internal positive control. PCR-based microsatellite instability analysis was performed using 7 microsatellites (TGFBR2 and the 6 National Cancer Institute recommended microsatellites, BAT25, BAT26, BAT40, D2S123, D5S346, and D17S250). A tumor was considered microsatellite instability-high if three or more of the seven markers demonstrated allelic shift. Tumors without allelic shift were designated as microsatellite stable.

Statistical analyses {#S7}
--------------------

Comparisons of cell-free DNA yield in relation to clinical and pathological characteristics were performed using ANOVA when there was homogeneity of variances. When the assumption of homogeneity was violated, the Kruskal Wallis test was applied. The Pearson correlation test was performed to determine the relationship between cell-free DNA yield and tumor size and tumor cellularity. Associations between tumor stage, tumor grade, myometrial invasion, and lymphatic/vascular space invasion with the detection of mutation in the plasma were performed using the Chi square test. When any of the assumptions of the Chi square test were violated, Fisher's exact test was performed. The association between mutation status, tumor size, and the initial cell-free DNA yield was determined by ANOVA with intra-class correlation measurements. For all analyses, *p* \< 0.05 was considered significant.

RESULTS {#S8}
=======

Clinical and pathological characteristics for the 48 endometrial cancer patients are summarized in [Table 1](#T1){ref-type="table"}. The mean age of the cohort was 58 years (range, 26--86), and most of the patients had early stage (Stage I or II), grade 2 tumors with less than 50% myometrial invasion at hysterectomy. The mean tumor size was 5.3 cm. Myometrial lymphatic/vascular space invasion was present in nearly half the tumors and was much more common in advanced stage cases. Note that no patients with grade 1 endometrioid tumors were included, as we did not have collected plasma for patients in this grade category. Mean patient age and mean tumor size were comparable between early stage and late stage patients. Overall, sixty-three per cent of the patients had mismatch repair intact tumors, while 37% were mismatch repair deficient.

The mean cell-free DNA yield extracted from the plasma samples was 15.6 ng/ml (range, 4.5--30 ng/ml). The presence of deep myometrial invasion was associated with significantly higher mean plasma cell-free DNA yield ([Figure 1](#F1){ref-type="fig"}). Pathological stage, tumor grade, and lymphatic/vascular space invasion, however, had no significant impact on mean plasma cell-free DNA ([Figure 1](#F1){ref-type="fig"}). Increased tumor size trended towards being associated with cell-free DNA yield (p=0.06). No correlation was found between the cell-free DNA yield and the starting tumor cellularity before tumor DNA extraction (p=0.416). Increasing patient age had no significant effect on the cell-free DNA yields (p= 0.212; data not shown).

The molecular findings for both tumor and plasma for the entire cohort are presented in [Figure 2](#F2){ref-type="fig"}. At least one mutation was detected in 45/48 (94%) of the tumors analyzed. Thirty patients (30/45, 66.7%) had at least one mutation in the tumor, but no matching mutations in the plasma. Fifteen patients (15/45, 33.3%) had at least one mutation in the tumor and the same matching mutation in the plasma. For 2 patients (9 and 18), a gene mutation was not detected in either tumor or plasma. For patient 21, *KRAS* and *PIK3CA* mutations were detected, but only in the plasma. Patients 1 and 32 had mutations in the tumor but different mutations in the plasma. Patient 1 had *PTEN* and *PIK3CA* mutations in the tumor that were also detected in the plasma. The plasma had a *KRAS* mutation and a second *PTEN* mutation; these were also in the tumor, but at allelic frequencies below 1%, well below our established 5% cut-off for calling mutations in the tumor. Patient 32 had only a *PTEN* mutation in the tumor, but the plasma had a *KRAS* mutation. This *KRAS* mutation was present in the tumor, but at 0.1% allelic frequency and therefore below the 5% cut-off for calling tumor mutations. Presence of mismatch repair deficiency in the tumor does not appear to be related to detetion of a mutation in the plasma. From [Figure 2](#F2){ref-type="fig"}, 31 patients did not have a mutation present in plasma. Ten of 31 (32%) of these had mismatch repair deficient tumors, while 21/31 (68%) had mismatch repair intact tumors. These percentages are nearly the same as the percentage of mismatch repair intact and deficient in the entire study cohort.

[Table 2](#T2){ref-type="table"} summarizes the comparisons of gene mutational frequencies between tumor and plasma. The most common mutations in the tumor were in *PTEN* and *PIK3CA*, with lower frequency of mutations in *KRAS* and *CTNNB1*, similar to our previous published work ([@R11]). In the plasma, *PTEN* and *PIK3CA* mutations were also the most common. For *PTEN* and *KRAS*, there was substantial drop-off in the detection of mutations in the plasma compared to tumor. For *PTEN*, 70.8% (34/48) of patients had at least one tumor mutation. Only 11/34 (32.4%) patients with a tumor *PTEN* mutation had the same *PTEN* mutation detected in plasma. For *KRAS*, 29.2% (14/48) of patients had a tumor mutation, but only 2/14 (14.3%) of these patients had the same *KRAS* mutation detected in plasma. The tumor-plasma mutational comparisons were more equitable for *CTNNB1* and *PIK3CA*, although for both of these genes mutations were more often detected in the tumor than plasma.

Fifteen of 45 patients (33%) had the same mutation detected in both the tumor and plasma. A more detailed summary of these patients is presented in [Table 3](#T3){ref-type="table"}. Remarkably, 8/15 (53.3%) of the patients with mutations detected in the plasma at the time of surgery presented at early stage (stage I or II), when the tumor is confined to the uterus. Overall, there were 24 stage IA patients in this cohort. Four of these (17% of stage IA) had a mutation detected in the plasma. Patients 5,10, and 42 were stage IA patients with the same mutations detected in the tumor and plasma ([Table 3](#T3){ref-type="table"}). The fourth stage IA patient (patient 32) had a *KRAS* mutation in the plasma that was present at very low allelic fraction in the tumor ([Table 4](#T4){ref-type="table"}). None of these patients with early stage disease and presence of plasma gene mutations had recurrence following surgery, but follow-up for most patients was limited ([Table 3](#T3){ref-type="table"}; mean follow-up time for early stage patients 2.4 years, range 0--6 years). A wide spectrum of mutations was identified in the 4 genes, suggesting that presence of mutation in plasma is not restricted to specific mutations in specific genes. Six of the patients had more than one mutation detected in both tumor and plasma.

Note from [Table 3](#T3){ref-type="table"} that 10/23 (43.5%) of the detected plasma mutations are at lower allelic frequency (less than 1%). A number of lines of evidence indicate that these low level mutations are not sequencing artifacts. One, the same mutation in each instance was identified in the matching tumor. Second, we never identified the same mutation when the matched buffy coat germline control was sequenced. Third, sequencing was repeated for these cases at higher depth, and the identical mutations at approximately the same allelic frequencies were identified. Fourth, using the same 4 gene next-generation sequencing platform, limiting dilution studies using the DLD1 colon cancer cell line detected mutations in *PIK3CA* and *KRAS* at 1% allelic frequency. Fifth, although we did not have sufficient residual plasma DNA for the more sensitive sequencing technique, digital droplet PCR, our previously published studies demonstrated that plasma mutations identified by next-generation sequencing at lower allelic frequencies were all verified by digital droplet PCR ([@R15]). The presence of plasma mutations at higher allelic frequencies (1% or greater) was observed in 4/8 (50%) of early stage patients and 2/7 (28.6%) of advanced stage patients ([Table 3](#T3){ref-type="table"}). Therefore, disease outside the uterus was not associated with detection of greater gene mutation allelic frequencies in the plasma.

For 3 patients, mutations detected in the plasma were present at very low allelic frequencies, less than 1%, in the tumor ([Table 4](#T4){ref-type="table"}). In our clinical laboratory, tumor mutations detected at less than 5% allelic frequency by next-generation sequencing are typically not reported. Next-generation sequencing was repeated for these tumors using a different sequencing platform to confirm the absence of tumor mutations at 5% or greater allelic frequency. Note that the *KRAS* G12D mutation detected in the plasma of patient 21 was present at relatively high allelic frequency (10%), but the same mutation was not identified at greater than 5% allelic frequency in the tumor. Patient 1 had 2 *PTEN* mutations in the plasma; R130G was detected at higher allelic frequency in the tumor ([Table 3](#T3){ref-type="table"}), while P213fs\*8 was detected at below 1% allelic frequency in the tumor ([Table 4](#T4){ref-type="table"}).

In [Table 5](#T5){ref-type="table"}, clinical/pathological characteristics of the 45 patients with at least one tumor mutation detected are stratified by mutation status of the plasma cell-free DNA. The plasma mutant group includes the 15 patients summarized in [Table 3](#T3){ref-type="table"}. Patients 9, 18, and 21 are excluded because no matching mutations were detected in their tumors at 5% or greater allelic frequency. Advanced tumor stage at the time of diagnosis, myometrial invasion ≥ 50% myometrial thickness, and presence of lymphatic/vascular invasion are associated with detection of a mutation in plasma. In addition, mean uterine primary tumor size in the plasma mutant group was significantly larger than tumor size in the plasma wildtype group. Importantly, pre-analytic factors such as total cell-free DNA yield, cell-free DNA input for sequencing library preparation, and primary tumor per cent cellularity had no significant impact on the ability to detect a gene mutation in plasma.

DISCUSSION {#S9}
==========

To our knowledge, this is the first publication in the peer-reviewed English literature which has identified endometrial cancer-associated mutations in the plasma of patients. Remarkably, a very limited panel of only 4 genes identified tumor mutations in over 90% of the cases studied. It is possible that by adding a few more genes more commonly mutated in endometrioid-type endometrial carcinomas, such as *ARID1A* and *PIK3R1* ([@R11]), an even higher percentage of endometrioid tumors could be captured by this panel. The ability to detect plasma-based mutations was dependent upon primary tumor characteristics, such as increased tumor size, advanced stage, deeper myometrial invasion, and the presence of lymphatic/vascular space invasion. The presence of mismatch repair deficiency in the tumor was not associated with increased likelihood of detecting mutations in the plasma. While the majority of the mutation-positive plasma cases were from patients with advanced stage disease (stages III and IV; endometrial cancer has spread beyond the uterus), we were surprised to find that nearly 20% of the early stage (stages I and II; endometrial cancer confined to the uterus) patients also had mutations detected in the plasma. We do not have follow-up blood samples from these patients. A more formal prospective study with multiple blood draws would be necessary to determine how soon after hysterectomy the mutations detected in plasma at the time of hysterectomy are cleared. Prospective studies could also help to determine if early stage patients with plasma-based mutations detected at the time of surgery are at increased risk for recurrence. These studies could also specifically investigate the incidence of plasma mutations in patients with grade 1 endometrioid tumors, which were not represented in this study. It would be expected that such patients would have smaller tumors and a lower incidence of myometrial lymphatic/vascular space invasion, which would likely impact detection of tumor-associated mutations in plasma in early stage patients.

For patients 1, 21, and 32, mutations detected in the plasma were not identified at 5% or greater allelic frequency in the tumor. The clinical significance of these mutations is unknown. As is the norm for molecular diagnostics testing, we examined mutations from one representative paraffin block of tumor. It is possible that if other paraffin blocks were available, one might harbor the mutations that were detected in the plasma. Such intra-tumoral heterogeneity has been identified in numerous systems, but how this heterogeneity should be accounted for in the clinical laboratory is currently uncertain. In one study, 3/69 (4.3%) of the colon cancers examined were wildtype for *KRAS* codon 12,13 mutations in the first block examined, but a mutation was detected in at least one additional block examined ([@R16]). Nearly 3% of the colon cancers examined had discordant *BRAF* V600E mutation status when assessing multiple paraffin blocks ([@R15]). Use of a 20 gene next-generation sequencing panel and testing 4 different areas of 87 colorectal adenocarcinomas demonstrated that 16% of mutation-positive cases had discordant mutations among the 4 areas sequenced ([@R17]). The most frequent genes demonstrating intra-tumoral heterogeneity were *PIK3CA* and *KRAS* ([@R17]). Sample pooling of DNA from multiple paraffin blocks ([@R16],[@R17]) has been proposed to mitigate such intra-tumoral heterogeneity. In theory, the use of liquid biopsy analysis of peripheral blood as a more comprehensive way to assess a tumor's molecular profile could substitute for the molecular testing of multiple paraffin blocks of tumor if the initial analyses demonstrated no mutation. This idea, however, has not been rigorously examined in a clinical setting. An alternative approach for the clinical laboratory would be to incorporate molecular barcodes, also known as unique identifiers, during library preparation for next-generation sequencing, as this would allow for more confidence in the assessment of low level mutations ([@R18],[@R19],[@R20]). The use of such molecular barcodes and digital droplet PCR ([@R15]) would be especially interesting to apply to patients with grade 1 endometrioid carcinomas, as these tumors tend to be smaller and with lower incidence of lymphatic/vascular space invasion.

Importantly, pre-analytical variables such as starting tumor per cent cellularity, cell-free DNA yield from plasma extraction, and mean cell-free DNA input for library preparation, were not significantly different between patients who had mutations detected in the plasma versus those who did not. In the current study, plasma was isolated from peripheral blood within 12 hours of the blood being collected into EDTA tubes, as per our standard tumor banking protocols. It is known that cell lysis after venipuncture when using standard EDTA tubes may result in contamination of tumor DNA with normal cell DNA (higher cell-free DNA) and decreased chances of detecting low level mutations ([@R21],[@R22]). Previously, it was shown that when plasma is separated from peripheral blood after sitting in EDTA tubes for more than 16 hours, the amount of isolated cell free DNA is significantly higher compared to plasma isolated from blood collected in Streck tubes ([@R13]). It is possible that some of the cases in which no mutations were detected in the plasma may be false negatives due to our use of EDTA collection tubes. Thus, another benefit of prospective studies is that the more optimal Streck collection tube can be used.

Although our work represents the first attempt to identify tumor-associated mutations in the plasma of endometrial cancer patients, there have been several prior studies that employed different approaches to molecularly characterize a tumor without studying the tumor itself. Two prior studies examined cervico-vaginal secretions collected on tampons for methylated gene sequences known to occur in endometrial cancer ([@R23],[@R24]). All 15 endometrial cancer patients examined had methylation of 3 or more genes detected in the cervico-vaginal secretions ([@R23]). In 38 patients with endometrial cancer, cervico-vaginal fluid gene methylation was significantly higher in 9/12 genes compared to individuals with benign endometrium ([@R24]). Analysis of the uterine cavity lavage fluid from 6 patients known to have endometrial cancer revealed mutations in *PTEN*, *PIK3CA*, *CTNNB1* or *APC* in all 6 cases ([@R25]). Uterine lavage fluid from 7 endometrial cancer patients yielded mutations in *PTEN*, *PIK3CA*, *KRAS*, *TP53*, or *CTNNB1* for each of the patients ([@R26]). For the tampon and uterine lavage fluid studies, presumably the source of gene mutations is from the primary tumor itself. It is unknown if mutations from the peripheral blood from a metastatic site outside the uterus could be detected in the tampons or uterine lavage fluid, although this possibility seems unlikely. Thus, while detecting mutations in tampons or uterine lavage fluid may have some utility as a means of early diagnosis of a primary endometrial cancer, these techniques would not be useful longitudinally for monitoring therapy of advanced disease that has spread outside the uterus. Detection of circulating tumor cells represents an alternative method to assessing mutations in plasma cell-free DNA. Previously, circulating tumor cells were identified from 6/40 (15%) endometrial cancer patients at the time of hysterectomy ([@R27]). Tumor stage, depth of myometrial invasion, and presence of lymphatic/vascular invasion, all factors influencing whether mutations were detected in plasma cell-free DNA in the current study, had no significant impact on detection of circulating tumor cells ([@R27]). For the 6 patients, only 1--2 circulating tumor cells were identified in each patient ([@R27]), which highlights a limitation to the widespread clinical applicability of this technique.

No matter the specific technique employed, the liquid biopsy approach has long been touted as a means of early cancer diagnosis or a way to perform cancer screening in at-risk individuals in a relatively non-invasive fashion. The use of liquid biopsy for this clinical application has pitfalls, however. It is known that somatic mutations in important driver genes are not restricted to malignancies. For example, it was recently demonstrated that 79% (19/24) of women with endometriosis had mutations in genes such as *ARID1A*, *KRAS*, and *PIK3CA* in the epithelial component of the endometriotic lesion tested ([@R28]). Mutations in each of these genes are relatively common in endometrioid endometrial carcinoma ([@R11]). Assuming the endometriosis-associated mutations could also be detected in peripheral blood, the finding of a plasma-based *KRAS*, *ARID1A*, or *PIK3CA* mutation in a woman during a screening test could not be assumed to mean that she had endometrial cancer. *PIK3CA* mutations can also occur in benign/premalignant skin lesions such as seborrheic keratosis (16%) and epidermal nevi (27%), but it is not known if the mutations from these skin lesions can be detected in a liquid biopsy ([@R29]). *TP53* mutations are common in non-endometrioid and grade 3 endometrioid endometrial carcinomas, but they can also be detected in approximately 9% of grade 1 or 2, early stage endometrioid carcinomas ([@R11]). However, *TP53* mutations can be found in the synovium of patients with rheumatoid arthritis ([@R30],[@R31]). *KRAS* mutations are also identified in colorectal adenomas ([@R32]). Because of the prevalence of relevant gene mutations in benign and premalignant conditions, caution should be exercised when considering the use of liquid biopsy as a cancer screening tool ([@R33]). A more conservative, but still useful, clinical application for liquid biopsy in endometrial cancer could be as a non-invasive method of monitoring a patient for recurrence following hysterectomy. In this scenario, it would be necessary to first characterize the molecular changes in the primary tumor, as any mutations identified in the tumor could then be tracked longitudinally in blood samples. From the current study, using a next-generation sequencing panel of only 4 genes, more than 90% of patients with endometrioid-type endometrial carcinoma have at least one mutation identified and could be potentially followed with serial liquid biopsies. Prospective studies are necessary to determine if plasma-based mutations in these genes could be detected years after the hysterectomy and whether detection of such plasma mutations is an early indicator of tumor recurrence.
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###### 

Clinical and pathological characteristics of the study cohort

  -------------------------------------------------------------------------------------------------------------------
  Characteristic                                                   All patients (n=48)   Early stage\   Late stage\
                                                                                         (n = 35)       (n=13)
  ---------------------------------------------------------------- --------------------- -------------- -------------
  Age in years, mean (s.d.)                                        58.0 (12.0)           58.3 (11.7)    58.1 (13.9)

  Endometrioid grade, n (%)                                                                             

  1                                                                0 (0%)                0 (0%)         0 (0%)

  2                                                                30 (62%)              24 (69%)       6 (46%)

  3                                                                18 (38%)              11 (31%)       7 (54%)

                                                                                                        

  ^[a](#TFN1){ref-type="table-fn"}^Myometrial invasion, n (%)                                           

  \<50%                                                            30 (64%)              27 (77%)       3 (25%)

  ≥ 50%                                                            17 (36%)              8 (23%)        9 (75%)

                                                                                                        

  ^[b](#TFN2){ref-type="table-fn"}^LVSI, N (%)                                                          

  No                                                               25 (53%)              24 (69%)       1 (8%)

  Yes                                                              22 (47%)              11 (31%)       11(92%)

                                                                                                        

  ^[c](#TFN3){ref-type="table-fn"}^Tumor size in cm, mean (s.d.)   5.3 (3.4)             5.1 (3.7)      5.8 (2.7)

                                                                                                        

  DNA mismatch repair                                                                                   

  Intact                                                           30 (63%)              24 (69%)       6 (46%)

  Deficient                                                        18 (37%)              11 (31%)       7 (54%)
  -------------------------------------------------------------------------------------------------------------------

Data missing for one patient.

LVSI, lymphatic/vascular space invasion; data missing for one patient.

Data missing for two patients

###### 

Detection of gene mutation in tumor and plasma for 48 patients

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
            Tumor Tissue n (%)                                                                                                                  
  --------- ------------------------------------------- ------------------------------------------- ------------------------------------------- -------------------------------------------
  Plasma\   Mutant                                      2 (14%)^[a](#TFN4){ref-type="table-fn"}^    3                                           5 (10%)^[b](#TFN5){ref-type="table-fn"}^
  cfDNA                                                                                                                                         

  WT        12 (86%)^[a](#TFN4){ref-type="table-fn"}^   31                                          43 (90%)^[b](#TFN5){ref-type="table-fn"}^   

  Total     14 (29%)^[b](#TFN5){ref-type="table-fn"}^   34 (71%)^[b](#TFN5){ref-type="table-fn"}^   48                                          

            *PTEN*^[c](#TFN6){ref-type="table-fn"}^                                                                                              

  Plasma\   Mutant                                      11 (32%)^[a](#TFN4){ref-type="table-fn"}^   0                                           11 (23%)^[b](#TFN5){ref-type="table-fn"}^
  cfDNA                                                                                                                                         

  WT        23 (68%)^[a](#TFN4){ref-type="table-fn"}^   14                                          37 (77%)^[b](#TFN5){ref-type="table-fn"}^   

  Total     34 (71%)^[b](#TFN5){ref-type="table-fn"}^   14 (29%)^[b](#TFN5){ref-type="table-fn"}^   48                                          

            *PIK3CA*                                                                                                                             

  Plasma\   Mutant                                      7 (33%)^[a](#TFN4){ref-type="table-fn"}^    1                                           8 (17%)^[b](#TFN5){ref-type="table-fn"}^
  cfDNA                                                                                                                                         

  WT        14 (67%)^[a](#TFN4){ref-type="table-fn"}^   26                                          40 (83%)^[b](#TFN5){ref-type="table-fn"}^   

  Total     21 (44%)^[b](#TFN5){ref-type="table-fn"}^   27 (56%)^[b](#TFN5){ref-type="table-fn"}^   48                                          

            *CTNNB1*                                                                                                                             

  Plasma\   Mutant                                      3 (27%)^[a](#TFN4){ref-type="table-fn"}^    0                                           3 (6%)^[b](#TFN5){ref-type="table-fn"}^
  cfDNA                                                                                                                                         

  WT        8 (73%)^[a](#TFN4){ref-type="table-fn"}^    37                                          45 (94%)^[b](#TFN5){ref-type="table-fn"}^   

  Total     11 (23%)^[b](#TFN5){ref-type="table-fn"}^   37 (77%)^[b](#TFN5){ref-type="table-fn"}^   48                                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The percentage of plasma gene mutation or wildtype detected was calculated of the total number of mutant cases in the tumor tissue column (n=14 for *KRAS*; n=34 for *PTEN*; n= 21 for *PIK3CA*; n=11 for *CTNNB1*).

The percentage was calculated of the total number of patients (n=48).

One patient (Patient 1 in [Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}) had 2 *PTEN* mutations detected in the plasma, R130G and P213fs\*8. R130G was present at high allelic fraction in the tumor, while P213fs\*8 was not detected in the tumor. Only the R130G mutation is considered for this table, since it was present in both tumor and plasma.

###### 

Summary of patients with same mutation detected in both tumor and matched plasma. AF, allelic frequency of mutation detected

  ----------------------------------------------------------------------------------------------------------
  Case \#             Stage   Endometrioid\   Tumor\        Gene Mutation       Tumor\   Plasma\   Buffy\
                              Grade           Recurrence                        AF       AF        Coat AF
  ------------------- ------- --------------- ------------- ------------------- -------- --------- ---------
  5                   I       2               None          *PIK3C* H1047Y      22       1.1       0

  *PTEN* H93R         26      1               0                                                    

  *PTEN* C136fs\*11   26      1               0                                                    

  10                  I       2               None          *PTEN* R130G        45       1         0

  14                  I       2               None          *PIK3CA* H1047R     22       1.2       0

  *CTNNB1* D32Y       20      2               0                                                    

  25                  I       3               None          *PTEN* I203fs\*14   32       0.5       0

  28                  I       2               None          *PTEN* L57fs\*42    40       0.6       0

  42                  I       2               None          *PTEN* T319\*       21       0.8       0

  48                  I       3               None          *PTEN* Q219\*       27       3         0

  *PTEN* L146\*       60      13              0                                                    

  *CTNNB1* S37C       39      3               0                                                    

  16                  II      3               None          *PIK3CA* E81K       36       0.2       0

  1                   III     3               Yes,\         *PIK3CA* Q546H      47       0.3       0
                                              vaginal\                                             
                                              cuff                                                 

  *PTEN* R130G        75      0.6             0                                                    

  4                   III     3               None          *PIK3CA* R88Q       34       0.3       0

  8                   III     3               Yes, pelvic   *PIK3CA* Y1021C     28       3.5       0

  *PTEN* V290\*       80      3.6             0                                                    

  11                  III     3               None          *PTEN* L267 fs\*9   34       0.5       0

  22                  III     2               Yes, colon    *PTEN* T131N        38       1.1       0

  *KRAS* G12D         22      1.1             0                                                    

  34                  III     3               No follow-\   *PTEN* R130G        35       0.9       0
                                              up                                                   

  43                  III     3               Yes, colon    *CTNNB1* S33F       30       0.2       0
  ----------------------------------------------------------------------------------------------------------

###### 

Mutations detected in the plasma and at very low allelic frequency (AF) in the tumor. LVSI, lymphatic/vascular invasion

  -------------------------------------------------------------------------------------------------------
  Case \#       Stage   Grade   Tumor\   Invasion\     LVSI   Gene mutation   Tumor\   Plasma\   Buffy\
                                Size\    Depth (%\                            AF       AF        Coat\
                                (cm)     Myometrial\                                             AF
                                         thickness)                                              
  ------------- ------- ------- -------- ------------- ------ --------------- -------- --------- --------
  1             III     3       6.2      85            yes    *KRAS* G13D     0.1      0.6       0

  *PTEN*\       0.6     0.8     0                                                                
  P213fs\*8                                                                                      

  21            III     2       6.5      100           yes    *PIK3CA* R88Q   0.2      0.6       0

  *KRAS* G12D   0.1     10      0                                                                

  32            I       2       1.6      7             no     *KRAS* G13S     0.1      0.6       0
  -------------------------------------------------------------------------------------------------------

###### 

Pathology characteristics of patients with endometrioid endometrial cancer, stratified by presence or absence of a gene mutation in the plasma at time of hysterectomy^[a](#TFN7){ref-type="table-fn"}^. cfDNA, cell-free DNA

  --------------------------------------------------------------------------------------------------------
  Characteristic                                           Plasma mutant      Plasma wildtype    P-value
  -------------------------------------------------------- ------------------ ------------------ ---------
  Tumor stage, n (%)                                                                             0.009

  Early                                                    8 (18%)            27 (60%)           

  Late                                                     7 (16%)            3 (7%)              

  Tumor grade, n (%)                                                                             0.077

  1                                                        0 (0%)             0 (0%)             

  2                                                        7 (16%)            22 (49%)           

  3                                                        8 (18%)            8 (18%)            

  ^[b](#TFN8){ref-type="table-fn"}^Myometrial invasion,\                                         0.018
  n (%)                                                                                          

  \<50%                                                    6 (14%)            24 (55%)           

  ≥ 50%                                                    8 (18%)            6 (14%)            

  ^[b](#TFN8){ref-type="table-fn"}^Lymphatic/vascular\                                           0.012
  invasion, n (%)                                                                                

  yes                                                      10 (23%)           9 (20%)            

  no                                                       4 (9%)             21 (48%)            

  Tumor size in cm, mean\                                  7.1 (5.0)          4.2 (2.0)          0.019
  (s.d.)                                                                                         

  Patient age in years,\                                   61 (14)            58 (11)            0.519
  mean (s.d)                                                                                     

  Tumor percentage,\                                       70% (20)           60% (19)           0.119
  mean (s.d.)                                                                                    

  cfDNA yield, mean\                                       16.1 ng/ml (7.7)   14.2 ng/ml (5.5)   0.463
  (s.d.)                                                                                         

  cfDNA input for library\                                 0.8 ng/ul (0.2)    0.8 ng/ul (0.2)    0.818
  preparation, mean (s.d.)                                                                       
  --------------------------------------------------------------------------------------------------------

The 45 patients for which at least one tumor mutation was identified are included in this analysis. Patients 9,18, and 21 are excluded.

Data missing for one patient.
